MDCX

Medicus Pharma Ltd (MDCX)

Market Open
29 Jul, 14:40
NASDAQ (CM) NASDAQ (CM)
$
2. 53
+0.09
+3.64%
$
46.68M Market Cap
- P/E Ratio
- Div Yield
100,640 Volume
- Eps
$ 2.44
Previous Close
Day Range
2.45 2.91
Year Range
1.8 8.94
Want to track MDCX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 2 days

Summary

MDCX trading today higher at $2.53, an increase of 3.64% from yesterday's close, completing a monthly decrease of -15.71% or $0.47. Over the past 12 months, MDCX stock gained 4.06%.
MDCX is not paying dividends to its shareholders.
The last earnings report, released on Jul 24, 2025, exceeded the consensus estimates by 0.39%. On average, the company has surpassed earnings expectations by 0.39%, based on the last three reports. The next scheduled earnings report is due on Jul 31, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

MDCX Chart

Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment

Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment

Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma (BCC) of the skin. The company is seeking a meeting during the week of October 6, aiming to gain the agency's approval to fast-track the program and seek feedback on future clinical plans.

Proactiveinvestors | 3 weeks ago
Medicus Pharma expands pipeline with Antev acquisition - ICYMI

Medicus Pharma expands pipeline with Antev acquisition - ICYMI

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest strategic developments. Bokhari discussed the definitive agreement to acquire Antev, a UK-based company advancing clinical programs for two indications.

Proactiveinvestors | 3 weeks ago
Medicus to acquire UK biotech Antev in share deal worth up to $65m

Medicus to acquire UK biotech Antev in share deal worth up to $65m

Medicus Pharma (NASDAQ:MDCX) has agreed to acquire Antev, a UK-based drug developer working on treatments for prostate conditions, in a share-based deal that could be worth up to US$65 million in future milestone payments. Under the terms of the agreement, Antev shareholders will receive 2.67 million Medicus shares, equivalent to around 17% of the enlarged company, and worth $7.7 million at current prices.

Proactiveinvestors | 4 weeks ago

Medicus Pharma Ltd (MDCX) FAQ

What is the stock price today?

The current price is $2.53.

On which exchange is it traded?

Medicus Pharma Ltd is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is MDCX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 46.68M.

When is the next earnings date?

The next earnings report will release on Jul 31, 2025.

Has Medicus Pharma Ltd ever had a stock split?

No, there has never been a stock split.

Medicus Pharma Ltd Profile

Biotechnology Industry
Healthcare Sector
Raza Bokhari MBA CEO
NASDAQ (CM) Exchange
CA58471K2020 ISIN
CA Country
12 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Medicus Pharma Ltd stands out as a leading entity in the pharmaceutical industry, concentrated on the research, development, and bringing to market innovative health care solutions. The core mission of the firm is to cater to unmet medical needs through the creation of a diversified portfolio of therapeutic treatments, concentrating primarily on areas such as oncology, neurology, and immunology. With a heavy reliance on biotechnology and avant-garde medical research, Medicus Pharma Ltd is firmly positioned as a significant figure in the life sciences domain. The organization is deeply committed to enhancing the quality and efficacy of treatments, thereby contributing significantly to the elevation of global healthcare standards. Beyond its influence on the pharmaceutical landscape, Medicus Pharma Ltd is instrumental in enhancing the health and well-being of patients and healthcare systems worldwide. As a frontrunner in the market, it engages in collaborations with academic bodies and industry counterparts, aiming to stimulate innovation and hasten the delivery of potentially life-saving drugs.

Products and Services

The range of products and services offered by Medicus Pharma Ltd is extensive, with each category tailored to address specific healthcare challenges:

  • Oncology Treatments: Medicus Pharma Ltd develops innovative therapies aimed at treating various forms of cancer. These treatments focus on improving patient outcomes and include targeted therapy, immunotherapy, and traditional chemotherapy. By leveraging the latest research in oncology, the company strives to offer more effective and less toxic options to patients.
  • Neurology Solutions: In the realm of neurology, the company is dedicated to discovering treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Through cutting-edge research, Medicus Pharma Ltd aims to provide patients with treatments that can alleviate symptoms, halt disease progression, and improve quality of life.
  • Immunology Therapies: Focusing on disorders of the immune system such as autoimmune diseases, Medicus Pharma Ltd is at the forefront of developing therapies that modulate the immune response. These treatments are designed to target underlying causes of immune-related conditions, offering new hope to patients suffering from diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease.

Each product and service provided by Medicus Pharma Ltd encapsulates the company's commitment to pioneering healthcare advancements, ensuring that their offerings not only meet the highest standards of safety and effectiveness but also address the evolving needs of patients and healthcare professionals around the globe.

Contact Information

Address: 300 Conshohocken State Rd. Suite 200
Phone: -